Phase II Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma of the Skin (cSCC)

Protocol No
ALLIANCE-A091802
Principal Investigator
Amy Harker-Murray
Phase
II
Summary
This study is being done to answer the following question: Can we increase the length of time you live with your cancer without your cancer getting worse (progression-free survival) by adding a new drug avelumab to another drug cetuximab in advanced squamous cell carcinoma of the skin, called cetuximab?
Description
Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Share This: